Pacific Biosciences of California, Inc.
PACB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $38 | $40 | $37 | $39 |
| % Growth | -3.3% | 7% | -5.3% | – |
| Cost of Goods Sold | $23 | $25 | $39 | $29 |
| Gross Profit | $16 | $15 | -$1 | $10 |
| % Margin | 41.4% | 36.9% | -3.7% | 25.6% |
| R&D Expenses | $23 | $23 | $29 | $27 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $31 | $36 | $40 | $41 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $358 | $94 |
| Operating Expenses | $54 | $60 | $428 | $163 |
| Operating Income | -$38 | -$45 | -$429 | -$153 |
| % Margin | -99% | -112.8% | -1,154.5% | -390.1% |
| Other Income/Exp. Net | $0 | $3 | $3 | $156 |
| Pre-Tax Income | -$38 | -$42 | -$426 | $3 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$38 | -$42 | -$426 | $2 |
| % Margin | -98.9% | -105.4% | -1,146.8% | 6% |
| EPS | -0.13 | -0.14 | -1.44 | 0.008 |
| % Growth | 7.1% | 90.3% | -17,242.9% | – |
| EPS Diluted | -0.13 | -0.14 | -1.44 | 0.008 |
| Weighted Avg Shares Out | 301 | 300 | 297 | 283 |
| Weighted Avg Shares Out Dil | 301 | 300 | 297 | 307 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $3 |
| Depreciation & Amortization | $3 | $5 | $373 | $11 |
| EBITDA | -$32 | -$36 | -$52 | $16 |
| % Margin | -84.3% | -89.5% | -139.6% | 41.8% |